Navigation Links
Enobia Raises US$50M from Current Investors in Series C Financing
Date:8/10/2009

MONTREAL, Aug. 10 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it raised US$50 million from its current investors in a Series C financing. The proceeds will be used primarily to fund the ongoing development program for ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia (HPP), a rare and potentially deadly genetic bone disorder for which there is no currently approved therapy. In addition, a portion of the proceeds will be used to fund an unspecified development program.

Participants in the financing include OrbiMed Advisors LLC ("OrbiMed") of New York, CTI Life Sciences Fund of Montreal ("CTI"), the Fonds de Solidarite FTQ, Desjardins Venture Capital and Lothian Partners. All previously participated in the CDN$40.1M Series B financing in August 2007.

"Enobia and our collaborators have been enormously pleased by the early clinical results in infants with severe hypophosphatasia. We are fortunate to have the ongoing support of knowledgeable investors helping the Company to advance the ENB-0040 development program," said Robert Heft, PhD, President and CEO of Enobia. "This new round of financing will provide the Company with sufficient capital to fund our activities through the first half of 2011 and to reach important clinical and manufacturing milestones."

"This financing underscores our enthusiasm for the potential of ENB-0040 in patients with HPP," said Jonathan Silverstein, Enobia Chairman and General Partner of OrbiMed. "We're pleased to build on our existing relationship with this team of scientists and management who are dedicated to finding treatments for this and other devastating rare bone disorders."

Six month safety and efficacy results of Enobia's Phase I/II study of ENB-0040 in infants with the severe form of HPP will be pr
'/>"/>

SOURCE Enobia Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
2. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Enobia Pharma Raises $40.1 Million Series B Financing
7. TSH Testing Raises Awareness of Importance of Thyroid Health
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
10. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
11. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
(Date:8/27/2015)... TRIANGLE PARK, N.C. , Aug. 27, 2015 ... on the decision by FedEx, UPS and The ... of certain biological specimens classified as ,select agents, ... and long history of handling these sensitive shipments. ... knowledge of global transportation regulations, trained and certified ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Calif., Oct. 14 GenVault Corporation today,announces that ... Senior Vice,President of Business Development. Mr. Sutherland will ... for partnering,and licensing the company,s products and technologies ... Mr. Sutherland has more than 25 years ...
... Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer ... that its,distributor, Laszlo Meszaros of Kardia Hungary Kft., ... for Budapest, Hungary., (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ... at the new MeDoc HealthCare Center,(MDHC) located in ...
... chosen to enable patient care services in Australia through ... ... 110th Annual Convention --,Mirixa Corporation, the leader in pharmacy-based patient ... Australia, announced,today that they have signed a definitive technology licensing ...
Cached Biology Technology:Mark Sutherland Joins GenVault as Senior Vice President, Business Development 2Imaging Diagnostic Systems Sells Its CT Laser Mammography System to Budapest, Hungary 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... studied human brain samples to isolate a set of proteins ... shows an intriguing link between diseases and the evolution of ... of medical disability in the developed world according to the ... exceeds $300 billion. The brain is the most complex ...
... Federal Ministry of Education and Research (BMBF) will fund ... (FRM II) by German and international researchers to the ... years. The Helmholtz Research Centers Juelich, Berlin, and Geesthacht ... budgets. The basis for these grants is the cooperation ...
... It,s just a worm, a tiny soil-dwelling nematode worm ... biology as shown in a recent study authored by University ... on the circadian clock of the Caenorhabditis elegans ... Biology . "Circadian rhythms are important in all ...
Cached Biology News:The genetic basis of brain diseases 2The genetic basis of brain diseases 3German federal government bolsters neutron research in Garching 2German federal government bolsters neutron research in Garching 3Breakthrough in worm research has implications for human disease studies 2
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
... Standard Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
Biology Products: